Celgene Corporation (CELG) Shares Bought by HighTower Advisors LLC

HighTower Advisors LLC raised its holdings in Celgene Corporation (NASDAQ:CELG) by 2.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 294,424 shares of the biopharmaceutical company’s stock after buying an additional 8,305 shares during the quarter. HighTower Advisors LLC’s holdings in Celgene were worth $38,242,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Thompson Davis & CO. Inc. raised its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 43 shares during the last quarter. Motco raised its stake in shares of Celgene by 19.3% in the second quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 159 shares during the last quarter. Penserra Capital Management LLC purchased a new position in shares of Celgene in the second quarter worth about $129,000. Acropolis Investment Management LLC purchased a new position in shares of Celgene in the second quarter worth about $144,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. raised its stake in shares of Celgene by 47.5% in the first quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 380 shares during the last quarter. Institutional investors own 80.17% of the company’s stock.

Shares of Celgene Corporation (NASDAQ CELG) opened at $102.14 on Monday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a market capitalization of $80,416.56, a P/E ratio of 15.96, a price-to-earnings-growth ratio of 0.79 and a beta of 1.78.

Celgene (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same period last year, the company earned $1.58 earnings per share. Celgene’s quarterly revenue was up 10.2% compared to the same quarter last year. equities research analysts anticipate that Celgene Corporation will post 6.67 EPS for the current year.

In other Celgene news, Director Michael D. Casey sold 9,250 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the sale, the director now directly owns 9,250 shares of the company’s stock, valued at $1,286,027.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares in the company, valued at $564,768.25. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,227 shares of company stock worth $2,843,956. 0.95% of the stock is owned by corporate insiders.

CELG has been the subject of several research analyst reports. Morgan Stanley cut Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective for the company. in a research note on Thursday, October 5th. BTIG Research restated a “hold” rating on shares of Celgene in a research note on Sunday, October 22nd. Cantor Fitzgerald reaffirmed a “hold” rating and set a $112.00 target price on shares of Celgene in a report on Monday, October 30th. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price on the stock in a report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 target price on Celgene and gave the stock a “buy” rating in a report on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $139.57.

ILLEGAL ACTIVITY NOTICE: This article was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.com-unik.info/2017/12/04/celgene-corporation-celg-shares-bought-by-hightower-advisors-llc.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit